Abstract:Glioblastoma is the most common type of malignant intracranial tumor in adults. Temozolomide (TMZ), as the first-line chemotherapy agent used in patients with glioblastoma, has demonstrated different effects in patients due to the expression of O6-methylguanine-DNA methyltransferase (MGMT) which is able to repair the DNA lesions induced by TMZ. The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is over-activated in glioblastoma and has been revealed to be potentially implicated in resistance to TMZ. BKM120, a selective pan class I PI3K inhibitor, has been reported to facilitate apoptosis and reverse drug resistance in advanced solid tumors. The present study aims to investigate whether BKM120 is able to sensitize glioma cells to TMZ. C6 glioma cells were treated with BKM120 and/or TMZ for 12, 24 and 48 h, respectively. Cell Counting Kit-8 assays were performed to determine cell viability. The level of apoptosis was evaluated by Hoechst 33342 and TUNEL staining, and the levels of cleaved caspase-3 and Bcl-2-like protein 4 (Bax) expression was measured. Furthermore, the present study investigated the possible mechanism underlying BKM120 reverse chemoresistance to TMZ. The downstream targets of PI3K, including phosphorylated (p)-Akt, nuclear factor (NF)-B p65, were analyzed by western blotting. The MGMT transcription levels in monotherapy and combination therapy were demonstrated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The present study revealed that monotherapy treatments with either drug required a high concentration found reduction in cell viability. However, a low concentration of BKM120 inhibited the PI3K/Akt/NF-kappa B signaling pathway activity in glioma cells and significantly increased TMZ cytotoxicity. The coefficient of drug interaction was similar to 0.7. Results from the TUNEL assay, Hoechst 33342 staining and evaluation of the levels of cleaved caspase-3 and Bax expression also confirmed the finding that the combination treatment induced a higher level of apoptosis compared with the TMZ monotherapy. RT-qPCR demonstrated that the combination strategy reversed the TMZ-induced MGMT over-transcription. The reduction of NF-kappa B p65 in combination treatment supported the hypothesis that BKM120 may mediate MGMT transcription via inhibition of NF-kappa B p65. In conclusion, BKM120 and TMZ demonstrated strong synergistic cytotoxicity in C6 glioma cells. The BKM120-induced NF-kappa B p65 inhibition may be involved in the mediation of MGMT transcription to reverse TMZ-resistance in C6 glioma cells.

Inhibition of Casein Kinase II by CX-4945, but Not Yes-associated Protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma

TTK Protein Kinase Promotes Temozolomide Resistance Through Inducing Autophagy in Glioblastoma.

Inhibition Of Elongation Factor-2 Kinase Augments The Antitumor Activity Of Temozolomide Against Glioma

EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.

Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma

Enhanced MGMT Expression Contributes to Temozolomide Resistance in Glioma Stem-Like Cells

Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells

Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma

Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells

Experimental Study of Selective MGMT Peptides Mimicking TMZ Drug Resistance in Glioma.

BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.

O6-methylguanine DNA Methyltransferase As a Promising Target for the Treatment of Temozolomide-Resistant Gliomas

A Novel Enhancer Regulates MGMT Expression and Promotes Temozolomide Resistance in Glioblastoma

Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis

IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Metformin and Temozolomide Act Synergistically to Inhibit Growth of Glioma Cells and Glioma Stem Cells in Vitro and in Vivo.

Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis